Woman says she was kicked off health insurance over ‘systematic failure' from federal agencies
She's not over 65 and she's not disabled, but the federal government says a metro Atlanta woman has actively been enrolled in Medicare for years.
'I should not be on Medicare. This is a systematic failure across several agencies,' Kristen Rose of Roswell told Channel 2 consumer investigator Justin Gray.
But last fall, she was told her Affordable Care Act health insurance for both her and her teenage son was canceled.
The notice of cancellation calls it 'voluntary withdrawal.'
'It said that I voluntarily withdrew, which was false. I never would have done that. Then, come to find out it was healthcare.gov that voluntarily withdrew me, and my insurance was immediately stopped,' Rose said.
Rose has had health insurance through the Obamacare ACA exchange for years with no problems, until suddenly she was told in October that she is not eligible because she is already enrolled in Medicare Part A.
TRENDING STORIES:
Fort Moore changed back to Fort Benning -- sort of
Apalachee High School football coach steps down for PTSD, anxiety counseling
2 accused in Atlanta shooting that led to death of 6-month-old boy to face judge
'I felt hopeless. I have no health insurance,' Rose said.
More than a decade ago, Rose was interviewed on Channel 2 Action News about the serious injuries she suffered because of a crash in a vehicle with recalled tires.
She went on Social Security disability at the time and was placed on Medicare.
But in 2018, she submitted a form as instructed saying she wished to discontinue disability and Medicare coverage.
For years, she thought that had happened.
'I didn't know I had Medicare. I had a premium. Never received a bill. Never received a card. I had no idea,' she said.
For months now, Rose has tried to work out the bureaucratic mix-up.
She was given a copy by Social Security of that same form she filled out back in 2018 to show Medicare. But her appeals were still denied.
Rose's credit score has dropped because Medicare has reported her for years of unpaid premiums and she's been unable for months to get expensive treatments for her rheumatoid arthritis.
'I need these medications. This is life sustaining. This has altered my life dramatically, not only physically, but mentally and emotionally,' Rose said.
The Social Security Administration told Channel 2 Action News that due to privacy rules they cannot discuss specific cases. But they did confirm they have reached out to Rose, after hearing from Gray.
Rose said that SSA now acknowledges a 'human error.
She was told they did in fact 'cancel' her Medicare back in 2018, however, they failed to 'terminate' it off her record.
Rose was told the termination has now been initiated and is being expedited.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Participants in program for elderly to rally in Lansing against Medicaid cuts
GRAND RAPIDS, Mich. (WOOD) — Potential Medicaid cuts in Congress could impact millions nationwide, including thousands in West Michigan. Advocates: Medicaid 'not a luxury,' lawmakers need plan for fallout At least 200 participants in the Program of All-Inclusive Care for the Elderly, or PACE, are visiting Lansing on Tuesday to urge state lawmakers to protect the program. PACE helps low-income seniors remain in their homes through care funded by Medicaid and Medicare. Sarah Milanowski, enrollment manager at LifeCircles PACE, said the issue affects both state and federal decision-makers. 'Medicaid is a state-administered program that has a portion of its funds from the federal government, and then the state matches funds,' she explained. 'So, as our local lawmakers are planning for their budget into the future, they are trying to hedge their bets about what might or might not be happening in Washington, D.C.' Republicans look for reset on Trump's 'big, beautiful bill' More than 2.6 million Michigan residents rely on Medicaid, according to the Michigan Department of Health and Human Services. That includes the 7,000 who use PACE services for medical care, transportation, prescriptions and more. PACE advocates are scheduled to meet with lawmakers starting at 9:30 a.m. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


Business Wire
4 hours ago
- Business Wire
Medimaps Group Expands in the U.S. With the Launch of TBS Osteo Next-Generation Software for Advanced Bone Microarchitecture Assessment
GENEVA--(BUSINESS WIRE)--Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, is further expanding its presence in the U.S. with the launch of its FDA-cleared next-generation TBS Osteo Advanced software. This milestone reflects the company's commitment to advancing osteoporosis detection and bone health management in the U.S. market with innovative solutions. With its cutting-edge technology, the TBS Osteo Advanced software delivers unmatched accuracy while remaining cost-effective. Share The TBS Osteo Advanced software delivers refined correction for soft tissue thickness anterior to the lumbar spine, ensuring inclusivity of TBS assessment across a wide range of body phenotypes. It also introduces new system management capabilities, allowing hospitals and healthcare networks to centrally manage the TBS software on their DXA systems fleet, and to standardize workflows across multiple locations. These improvements enhance operational efficiency, streamline clinical processes, and ensure consistent patient care. TBS Osteo is available through a convenient subscription model, a flexible option providing customers with eligibility for software updates, new features and support services. This approach ensures healthcare organizations stay up to date with the latest innovations in osteoporosis care. Current TBS Osteo users have the possibility to upgrade to the next generation version and to take advantage of the new capabilities. 'With its cutting-edge technology, the TBS Osteo Advanced software delivers unmatched accuracy while remaining cost-effective. Designed for seamless integration into clinical workflows, it requires no additional exam time or extra appointments - an essential advantage for busy radiology professionals,' said Univ. Prof. Dr. Didier Hans, CEO and Co-founder of Medimaps Group. 'Its proven impact on patient care, ease of use, and its reimbursement status set it apart from competing technologies, reinforcing its presence in the vast majority of the U.S.' top-ranked hospitals.' Since its initial launch in 2012, TBS Osteo has been widely adopted across the U.S., including by 16 of the top 20 hospitals and healthcare providers, to support the assessment and management of osteoporosis. The software is backed by over 1,400 peer-reviewed publications and endorsed by 30 national and international clinical guidelines for its use in fracture risk assessment with DXA imaging. In the U.S., the software has received clearance from the Food and Drug Administration (FDA) and remains the only approved medical software for bone microarchitecture evaluation in clinical practice. Since 2022, Medicare has reimbursed TBS Osteo through four Category 1 CPT codes - 77089, 77090, 77091, and 77092 - offering additional reimbursement beyond standard DXA scan coverage. This recognition highlights the growing importance of comprehensive bone health assessments in the fight against osteoporosis. Osteoporosis is a condition that weakens bones and increases the risk of fractures. According to the Bone Health & Osteoporosis Foundation (BHOF), approximately 10 million Americans have osteoporosis, while another 44 million have low bone density, putting them at risk if left untreated. In total, 54 million Americans - half of all adults aged 50 and older - are at risk of breaking a bone due to osteoporosis. About Medimaps Group Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone health management. We provide healthcare professionals worldwide with advanced AI-driven software that enables comprehensive bone microarchitecture assessment. Our passion for musculoskeletal health is underpinned by scientific knowledge, collaborations with world-class academics, clinicians, industry partners, and direct patient engagement. The science behind our cutting-edge imaging applications and clinical evidence forms the core of our company's DNA. Medimaps Group, headquartered in Geneva, Switzerland, has offices in the United States and France. Its U.S. affiliate, Medimaps Group USA LLC, markets the company products and services. Learn more at
Yahoo
4 hours ago
- Yahoo
Drug maker sues over new North Dakota pharmaceutical law
A pharmacy manager retrieves a bottle of antibiotics. (Photo by) North Dakota is being sued over a new law that requires drug manufacturers to sell more of their medications at a discount. House Bill 1473, signed by Gov. Kelly Armstrong in April, primarily affects drug companies participating in a federal program called 340B. A drug manufacturer has filed suit over the policy in North Dakota federal court, claiming it is unconstitutional and will hurt its profits. The state denies the company's claims. The 340B program was created by Congress in 1992 to improve health care access in low-income communities. It requires participating drug companies to offer discounted products to qualifying hospitals and other medical facilities. Drug companies must take part in 340B in order to participate in federal Medicaid and Medicare programs. In legislative hearings, proponents of the bill called 340B a critical program for rural North Dakota, subsidizing medication for patients and allowing hospitals to provide a wider range of services. 'This is a lifeblood to rural facilities across the state,' Rep. Jon Nelson, a Rugby Republican and bill sponsor, said during a February committee meeting. North Dakota this year became one of a handful of states to pass a law limiting drug manufacturers' freedom to decide where and how they sell 340B drugs. House Bill 1473 makes it a class B misdemeanor for companies to adopt policies that 'deny, restrict, prohibit, or otherwise interfere' with pharmacies' ability to obtain and dispense products to patients on behalf of 340B hospitals. In testimony on the proposal, hospital representatives complained that drug companies were cutting off access to medications subsidized through 340B, namely by refusing to sell the drugs to more than one pharmacy hospitals work with. In an April complaint filed against North Dakota, drug company AbbVie argued that Congress intended for manufacturers to be able to set additional requirements for 340B hospitals to access their products — so long as the medications are offered at the reduced costs mandated by the program. The company alleges that pharmacies and hospitals are taking advantage of the 340B program by selling the discounted medications at full price. Barring drug manufacturers from placing additional parameters on these sales will only harm the low-income patients the program is intended to benefit, AbbVie wrote in its complaint. In testimony in favor of House Bill 1473, hospital and pharmacy representatives said that the real reason drug companies are reluctant to sell discounted drugs to more pharmacies is because they want to sell their medication at list price at as many places as possible. AbbVie also alleges that North Dakota is trying to use a state law to change a federal program, which they say is a violation of the U.S. Constitution's Supremacy Clause. Any changes to how 340B operates must be approved by Congress, the company argues. They claim that federal law makes the U.S. Department of Health and Human Services the sole agency in charge of enforcing 340B compliance, leaving no room for state policies like House Bill 1473. The company further argues that the law is an illegal attempt to regulate business in other states. Since some North Dakota hospitals have agreements with pharmacies across state lines, House Bill 1473 could affect transactions between out-of-state drug companies and pharmacies — which AbbVie says is unconstitutional. According to the company, the law also violates rights protected under the Fifth Amendment by forcing it to sell its property to a private party. Companies found in violation of the new law, which takes effect Aug. 1, could face 30 days in jail, a maximum fine of $1,500, or both. The North Dakota Board of Pharmacy can also impose civil penalties on violators, according to testimony on the bill. AbbVie has asked a federal judge to declare House Bill 1473 unconstitutional and to order that North Dakota cannot enforce it. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX Courts across the country have ruled differently on this issue. The D.C. Circuit Court of Appeals and Third Circuit Court of Appeals have both ruled the 340B program does not prevent drug companies from imposing additional requirements on hospitals and pharmacies, the drug manufacturer noted in court filings. However, the Eighth Circuit in 2024 upheld an Arkansas law similar to House Bill 1473. The Arkansas law makes it illegal for drug companies to prevent hospitals from using pharmacies to get 340B drugs into the hands of patients. The Eighth Circuit includes North Dakota, South Dakota, Minnesota, Iowa, Missouri, Kansas, Nebraska and Arkansas. SUPPORT: YOU MAKE OUR WORK POSSIBLE